NURIX THERAPEUTICS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $84.0M | $54.5M | $77.0M | $38.6M | $29.8M | $17.8M | $31.1M |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $316.9M | $221.6M | $189.1M | $184.5M | $116.4M | $66.5M | $45.0M |
| SG&A Expense | $52.7M | $45.9M | $42.9M | $38.0M | $31.2M | $16.3M | $8.3M |
| Operating Income | $-285.7M | $-213.0M | $-155.1M | $-183.9M | $-117.9M | $-65.0M | $-22.2M |
| Operating Margin | -340.2% | -390.5% | -201.4% | -476.0% | -396.3% | -364.7% | -71.5% |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | $-263.7M | $-193.3M | $-143.9M | $-180.4M | $-117.1M | $-63.8M | $-21.5M |
| Income Tax Expense | $760.0K | $270.0K | $0 | $0 | $131.0K | $-20.5M | $239.0K |
| Net Income | $-264.5M | $-193.6M | $-143.9M | $-180.4M | $-117.2M | $-43.2M | $-21.7M |
| Net Margin | -314.9% | -354.9% | -187.0% | -466.9% | -393.9% | -242.7% | -69.7% |
| EPS (Basic) | $-3.05 | $-2.88 | $-2.65 | $-3.71 | $-2.73 | $-2.76 | $-6.59 |
| EPS (Diluted) | $-3.05 | $-2.88 | $-2.65 | $-3.71 | $-2.73 | $-2.76 | $-6.59 |
| Shares Outstanding (Basic) | 86.7M | 67.1M | 54.3M | 48.6M | 42.9M | 38.9M | 3.6M |
| Shares Outstanding (Diluted) | 86.7M | 67.1M | 54.3M | 48.6M | 42.9M | 38.9M | 3.6M |
| Dividends Per Share | $0.00 | $0.00 | — | — | — | $0.00 | $0.00 |